Goel, S., Blancas, I., Allegrini, G., Alonso-Romero, J. L., Rodriguez-Lescure, A., Cobo, S. L., Grela-Wojewoda, A., Grinda, T., Villanueva, C., Sarti, S., Kurzeder, C., Cikman, I., Beeram, M., Lee, K., Basu, C., Kim, S., Liu, F., Yao, J., Ignatiadis, M. (2026). Neoadjuvant atirmociclib plus letrozole versus letrozole alone in HR+/HER2− breast cancer: Results from FourLight-2, a randomized phase 2 window of opportunity study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.518